SCHEMBL22730236

SCHEMBL22730236

CC(C)(Cc1ccccc1)C[SiH](I)C(C)(C)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.41
SLC6A2 P23975 1/20 0.41
CYP2C19 P33261 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
LMNA P02545 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP3A4 P08684 2/20 0.36
RECQL P46063 1/20 0.36
TRPA1 O75762 1/20 0.35
MAPK1 P28482 2/20 0.35
HIF1A Q16665 1/20 0.34
KIF11 P52732 2/20 0.33
MMP8 P22894 2/20 0.33
KCNA5 P22460 1/20 0.33
RAB9A P51151 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22730248 0.82 CYP2C19 (0.36) TAAR1CYP2C19CYP3A4MAPK1HIF1A
SCHEMBL22730240 0.80 CYP2C19 (0.39) TAAR1CYP2C19CYP3A4MAPK1HIF1A
SCHEMBL22730166 0.79 TAAR1 (0.41) TAAR1SLC6A2CYP2C19CYP1A2CYP2C9
SCHEMBL22730228 0.79 TAAR1 (0.41) TAAR1SLC6A2CYP2C19CYP1A2CYP2C9
SCHEMBL22730195 0.75 CYP2C19 (0.36) TAAR1CYP2C19CYP3A4MAPK1HIF1A
SCHEMBL22734818 0.74 CYP2C19 (0.41) TAAR1CYP2C19CYP2C9CYP2D6CYP3A4
SCHEMBL1572105 0.72 SLC6A2 (0.64) TAAR1SLC6A2CYP2C19CYP1A2CYP2C9
SCHEMBL22730173 0.69 CYP2C19 (0.37) TAAR1CYP2C19CYP3A4MAPK1HIF1A
SCHEMBL22730159 0.69 CYP2C19 (0.34) TAAR1CYP2C19MAPK1HIF1AALDH1A1
SCHEMBL1269138 0.69 SLC6A2 (0.54) TAAR1SLC6A2CYP2C19CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066427-B2 Organosilane compounds having bulky substituent and preparation thereof SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-07-20 US disclosed
US-20200385411-A1 ORGANOSILANE COMPOUNDS HAVING BULKY SUBSTITUENT AND PREPARATION THEREOF SHIN-ETSU CHEMICAL CO., LTD. (JP) 2020-12-10 US disclosed
EP-3747889-A1 ORGANOSILANE COMPOUNDS HAVING BULKY SUBSTITUENT AND PREPARATION THEREOF Shin-Etsu Chemical Co., Ltd. (JP) 2020-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066427-B2 Organosilane compounds having bulky substituent and preparation thereof C1S, C1R, C9 TAAR1 1233/4885SLC6A2 4250/4885CYP2C19 170/4885
US-20200385411-A1 ORGANOSILANE COMPOUNDS HAVING BULKY SUBSTITUENT AND PREPARATION THEREOF C1S, C1R, C9 TAAR1 1233/4885SLC6A2 4250/4885CYP2C19 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.